Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal
China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive...
Cancer
Our United Corporation’s Linear Accelerator Approved as Innovative Medical Device by NMPA
Xi’an-based Our United Corporation has announced that its medical electronic linear accelerator has been approved...
BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023
BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene...
ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma
Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from...
CASI Pharmaceuticals Enters Assignment Agreement with Mundipharma for Folotyn Commercialization in China
US-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has announced the execution of an assignment agreement with...
Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...
GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer
GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...
RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...
Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...
Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment
China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...
Lucence and Innovent Biologics Partner to Enhance Access to Cholangiocarcinoma Treatment in Hong Kong
Singapore-based precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto...
Mirxes Holding Company Secures USD 50 Million in Series D Financing for RNA Technology
Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...
HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study
Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...
InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study
Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...
FDA Approves Daiichi Sankyo’s Vanflyta for FLT3-ITD Positive AML Maintenance Treatment
The US Food and Drug Administration (FDA) has granted clearance to Japan-based Daiichi Sankyo (TYO:...
Gilead Sciences Halts Development of Magrolimab for HR-MDS Following Phase III Trial Results
Gilead Sciences (NASDAQ: GILD) has decided to stop pursuing the potential first-in-class immunotherapy, magrolimab, for...
AbbVie’s Aquipta and Novartis’s Piqray Receive Regulatory Approvals in Mexico
Mexico’s Federal Commission for Protection against Health Risks (COFEPRIS) has granted registration approvals to two...
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...